BCG vaccine

ApprovedVaccine

GGynecologic Oncology Group

BCG vaccine is one of 570 biologic programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

569

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

Urinary Bladder CarcinomaUnknown

Lung CancerActive, not recruiting

MortalityActive, not recruiting

HIV-1 InfectionActive, not recruiting

Alzheimer DiseaseActive, not recruiting

NeuroblastomaActive, not recruiting

SepsisActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Adverse EffectActive, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Urinary Bladder CarcinomaPreclinical

Unknown

Lung CancerPhase 3

Active, not recruiting

MortalityPhase 3

Active, not recruiting

HIV-1 InfectionPhase 2

Active, not recruiting

Alzheimer DiseasePhase 1

Active, not recruiting

NeuroblastomaPhase 1

Active, not recruiting

SepsisPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Adverse EffectPreclinical

Active, not recruiting

Showing 10 of 21 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

BCG vaccine

GGynecologic Oncology Group

Approved

1 2

Lexiscan

Astellas

Preclinical

1 3

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 4

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 8

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 9

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 10

Systemic Treatment

TTaproot Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Vaccines

NCT04899765

Q4 2028

Post-ApprovalRecruiting

Immune Response

NCT06148025

Q3 2029

Post-ApprovalActive, not recruiting

Prevention

NCT05591339

Clinical

Trials by Indication[1]

COVID-199 trials

BCG Vaccination to Protect Healthcare Workers Against COVID-19

Completed·MMurdoch Childrens Research Institute·Phase 3·NCT04327206·6,828 enrolled

Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers

Unknown status·UUniversidade Federal do Rio de Janeiro·Phase 2·NCT04659941·752 enrolled

BCG Vaccine for Health Care Workers as Defense Against COVID 19

Completed·TTexas A&M University·Phase 4·NCT04348370·659 enrolled

Show 6 more trials

Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers

Unknown status·HHospital Universitario Dr. Jose E. Gonzalez·Phase 3·NCT04461379·908 enrolled

Bacillus Calmette-guérin Vaccination to Prevent COVID-19

Completed·HHellenic Institute for the Study of Sepsis·Phase 4·NCT04414267·301 enrolled

Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination

Unknown status·RRadboud University Medical Center·Phase 4·NCT04417335·2,014 enrolled

Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine

Completed·UUMC Utrecht·Phase 3·NCT04328441·1,511 enrolled

BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)

Withdrawn·HHarvard Medical School (HMS and HSDM)·Phase 3·NCT04534803

The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines

Active, not recruiting·OOswaldo Cruz Foundation·Phase 3·NCT05507671·556 enrolled

Bladder Cancer7 trials

Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer

Completed·MMedical Research Council·Phase 3·NCT00002490

BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00004122

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

Completed·AA.O.U. Città della Salute e della Scienza·Phase 2·NCT01697306·120 enrolled

Show 4 more trials

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00023842·97 enrolled

Surgery and BCG in Treating Patients With Bladder Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002990·1,288 enrolled

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

Completed·AAnthra Pharmaceuticals·Phase 2·NCT00003759

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Terminated·NNCIC Clinical Trials Group·Phase 3·NCT00352079·41 enrolled

Immune Response2 trials

Effects of BCG on Immune Response

Completed·RRadboud University Medical Center·Phase 2/3·NCT02085590·20 enrolled

Antibiotics and Vaccine Immune Responses Study

Recruiting·SSouth Australian Health and Medical Research Institute·Phase 4·NCT06148025·348 enrolled

Vaccination2 trials

BCG Revaccination in Children and Adolescents

Suspended·TTuberculosis Research Centre, India·Phase 3·NCT05330884·9,200 enrolled

Safety and Tuberculin Conversion Following BCG Vaccination

Completed·PPT Bio Farma·Phase 2·NCT05124340·220 enrolled

Vaccines2 trials

Measles and BCG Vaccines for Mother and Child

Recruiting·BBandim Health Project·Phase 4·NCT04899765·2,400 enrolled

Live Vaccines and Innate Immune Training in COPD.

Completed·JJosefin Eklöf·Phase 4·NCT06257212·60 enrolled

19 more indications

Small Cell Lung Cancer2 trials

Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00006352·453 enrolled

Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003279·500 enrolled

Bladder Carcinoma1 trial

Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Completed·AAnchiano Therapeutics Israel Ltd.·Phase 1·NCT01878188·38 enrolled

Diphtheria1 trial

BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa

Enrolling by invitation·BBandim Health Project·Phase 4·NCT07005726·6,000 enrolled

Prostate Cancer1 trial

Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer

Unknown status·KKael-GemVax Co., Ltd.·Phase 2·NCT00514072·54 enrolled

Melanoma1 trial

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Terminated·AAVAX Technologies·Phase 2·NCT00003715·425 enrolled

Immunogenicity1 trial

Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Withdrawn·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group·Phase 1/2·NCT05539989

Hepatitis B1 trial

A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study

Completed·MMurdoch Childrens Research Institute·N/A·NCT02444611·185 enrolled

Respiratory Infection1 trial

Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly

Withdrawn·HHarvard Medical School (HMS and HSDM)·Phase 2/3·NCT04938323

Colon Cancer1 trial

Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery

Completed·NNSABP Foundation Inc·Phase 3·NCT00427570

Breast Cancer1 trial

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Completed·PProvidence Cancer Center, Earle A. Chiles Research Institute·Phase 1·NCT00003184

Metastatic Colorectal Cancer1 trial

Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Unknown status·OOnyvax·Phase 1/2·NCT00007826

Monoclonal1 trial

Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003023·24 enrolled

Stage III Colon Cancer1 trial

Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery

Completed·IIntracel·Phase 1/2·NCT00016133

Alzheimer's Disease1 trial

Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?

Enrolling by invitation·TTamir Ben-Hur·Phase 1·NCT06078891·60 enrolled

Adverse Effect1 trial

BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects .

Unknown status·—·N/A·NCT03548233·100 enrolled

Stage IV Ovarian Epithelial Cancer1 trial

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Terminated·GGynecologic Oncology Group·Phase 2·NCT00003386

Prevention1 trial

Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau

Active, not recruiting·BBandim Health Project·Phase 4·NCT05591339·200 enrolled

Tuberculosis1 trial

Immunization With BCG Vaccine to Prevent Tuberculosis Infection

Terminated·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 3·NCT04453293·16 enrolled

Mortality1 trial

BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots

Completed·TTuberculosis Research Centre, India·Phase 3·NCT04475302·2,175 enrolled

Sources

References

[1]
ClinicalTrials.gov — 42 trial records for BCG vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCG vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCG vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: GGynecologic Oncology Group

BCG vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Q3 2029

Trials by Indication[1]

COVID-199 trials

Bladder Cancer7 trials

Immune Response2 trials

Vaccination2 trials

Vaccines2 trials

Small Cell Lung Cancer2 trials

Bladder Carcinoma1 trial

Diphtheria1 trial

Prostate Cancer1 trial

Melanoma1 trial

Immunogenicity1 trial

Hepatitis B1 trial

Respiratory Infection1 trial

Colon Cancer1 trial

Breast Cancer1 trial

Metastatic Colorectal Cancer1 trial

Monoclonal1 trial

Stage III Colon Cancer1 trial

Alzheimer's Disease1 trial

Adverse Effect1 trial

Stage IV Ovarian Epithelial Cancer1 trial

Prevention1 trial

Tuberculosis1 trial

Mortality1 trial

References

Drug Info

Quick Facts

Related News